Adam V. Patterson

6.7k total citations
154 papers, 5.2k citations indexed

About

Adam V. Patterson is a scholar working on Molecular Biology, Cancer Research and Biotechnology. According to data from OpenAlex, Adam V. Patterson has authored 154 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 66 papers in Cancer Research and 35 papers in Biotechnology. Recurrent topics in Adam V. Patterson's work include Cancer, Hypoxia, and Metabolism (64 papers), Cancer Research and Treatments (35 papers) and Virus-based gene therapy research (21 papers). Adam V. Patterson is often cited by papers focused on Cancer, Hypoxia, and Metabolism (64 papers), Cancer Research and Treatments (35 papers) and Virus-based gene therapy research (21 papers). Adam V. Patterson collaborates with scholars based in New Zealand, United Kingdom and China. Adam V. Patterson's co-authors include Jeff B. Smaill, William R. Wilson, Ian J. Stratford, Christopher P. Guise, Adrian L. Harris, Gabi U. Dachs, Alexandra M. Mowday, William A. Denny, Ke Ding and David F. Ackerley and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Adam V. Patterson

153 papers receiving 5.0k citations

Peers

Adam V. Patterson

ONCOL

BIOTE

Niramol Savaraj United States

Carlos M. Galmarini Spain

Gabi U. Dachs New Zealand

Shashi Gujar Canada

Andrew P. Mazar United States

Mónica L. Guzmán United States

D. Paul Harkin United Kingdom

Graziella Pratesi Italy

Moorthy P. Ponnusamy United States

Macus Tien Kuo United States

Niramol Savaraj United States

Adam V. Patterson

3.2k ×1.2

1.7k ×0.9

2.4k ×2.3

ONCOL

1.1k ×1.3

BIOTE

335 ×0.5

Citations per year, relative to Adam V. Patterson Adam V. Patterson (= 1×) peers Niramol Savaraj

Countries citing papers authored by Adam V. Patterson

Since Specialization

Citations

This map shows the geographic impact of Adam V. Patterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam V. Patterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam V. Patterson more than expected).

Fields of papers citing papers by Adam V. Patterson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam V. Patterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam V. Patterson. The network helps show where Adam V. Patterson may publish in the future.

Co-authorship network of co-authors of Adam V. Patterson

This figure shows the co-authorship network connecting the top 25 collaborators of Adam V. Patterson. A scholar is included among the top collaborators of Adam V. Patterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam V. Patterson. Adam V. Patterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Xiaofei, et al.. (2026). Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors. Journal of Medicinal Chemistry. 69(5). 5199–5218.

Ling, Yan, Xiaojuan Song, Zhang Lin, et al.. (2025). Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance. Journal of Medicinal Chemistry. 68(18). 19415–19437. 1 indexed citations

Xu, Fang, Xin Zhang, Zhipeng Chen, et al.. (2022). Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells. Journal of Medicinal Chemistry. 65(20). 14032–14048. 28 indexed citations

Ashoorzadeh, Amir, Alexandra M. Mowday, Christopher P. Guise, et al.. (2022). Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications. Pharmaceuticals. 15(2). 185–185. 3 indexed citations

Lu, Xiaoyun, Jeff B. Smaill, Adam V. Patterson, & Ke Ding. (2021). Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. Journal of Medicinal Chemistry. 65(1). 58–83. 91 indexed citations

Chen, Xiaojuan, Xiaojuan Song, Minhao Huang, et al.. (2021). Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. ACS Medicinal Chemistry Letters. 12(4). 647–652. 14 indexed citations

Yosaatmadja, Y., Martin Middleditch, Zhen Zhang, et al.. (2019). Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. ACS Medicinal Chemistry Letters. 10(8). 1180–1186. 22 indexed citations

Lu, Xiaoyun, et al.. (2018). Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. Journal of Medicinal Chemistry. 62(6). 2905–2915. 60 indexed citations

Zhang, Zhang, Christopher P. Guise, Xueqiang Li, et al.. (2017). 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Medicinal Chemistry Letters. 8(5). 543–548. 34 indexed citations

10.

Wang, Jingli, Christopher P. Guise, Gabi U. Dachs, et al.. (2014). Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. Biochemical Pharmacology. 91(4). 436–446. 29 indexed citations

11.

Green, Laura K., Sophie P. Syddall, Christopher P. Guise, et al.. (2013). Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy. Molecular Cancer. 12(1). 58–58. 15 indexed citations

12.

Gu, Yongchuan, Frederik B. Pruijn, Jeff B. Smaill, et al.. (2013). Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence. Journal of Biological Chemistry. 288(52). 37138–37153. 18 indexed citations

13.

Meng, Fanying, James Evans, Monica Banica, et al.. (2011). Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302. Molecular Cancer Therapeutics. 11(3). 740–751. 160 indexed citations

14.

Guise, Christopher P., Maria R. Abbattista, Rachelle S. Singleton, et al.. (2010). The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3. Cancer Research. 70(4). 1573–1584. 141 indexed citations

15.

Wilson, William R., Stephen M. Stribbling, Frederik B. Pruijn, et al.. (2009). Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N 3 DNA minor groove alkylators. Molecular Cancer Therapeutics. 8(10). 2903–2913. 29 indexed citations

16.

Gu, Yongchuan, Adam V. Patterson, Graham J. Atwell, et al.. (2009). Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Molecular Cancer Therapeutics. 8(6). 1714–1723. 52 indexed citations

17.

Singleton, Rachelle S., Christopher P. Guise, Dianne M. Ferry, et al.. (2009). DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity. Cancer Research. 69(9). 3884–3891. 60 indexed citations

18.

Ahn, G‐One, et al.. (2008). Optimized Clostridium -Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104. Cancer Research. 68(19). 7995–8003. 53 indexed citations

19.

Ahn, G‐One, et al.. (2006). Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochemical Pharmacology. 71(12). 1683–1694. 67 indexed citations

20.

Patterson, Adam V., Mark Saunders, & Olga Greco. (2003). Prodrugs in Genetic Chemoradiotherapy. Current Pharmaceutical Design. 9(26). 2131–2154. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact